Condition

Lymphocytic

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common interventions4

Lead sponsors shown2

Clinical trials

3 shown

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte LeukemiaNCT03759184 · 2019-07-11

TERMINATED

A Safety and Tolerability Study of PCI-24781 in Subjects With CancerNCT01149668 · 2010-06-01

COMPLETED

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic LeukemiaNCT00077922 · 2004-02-29

COMPLETED

Common interventions

LMB-2DRUG1 ObinutuzumabBIOLOGICAL1 PCI-24781DRUG1 rhIL-15DRUG1

Leading sponsors

National Cancer Institute (NCI)2 Pharmacyclics LLC.1

Trial status mix

COMPLETED2

TERMINATED1

Phase mix

PHASE12

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.